The global Hematologic Malignancies Testing Market had a size of USD 2.55 billion in 2021 and is expected to grow at a CAGR of 14.7% during the forecast period. Hematologic malignancies are cancers that develop in blood, bone marrow, and lymph nodes.
The rising prevalence of blood cancer, leukemia, and multiple myeloma worldwide, increasing healthcare spending, awareness among patients and healthcare professionals about early diagnosis, and the development of a strong product pipeline are the main factors driving market revenue growth.
Get a free sample PDF of the report, visit @
https://www.reportsanddata.com/download-free-sample/5908
Hematologic malignancies are one of the leading causes of death in the U.S., accounting for 9.5% of cancer deaths in 2021, and the incidence rates of non-Hodgkin's lymphoma and leukemia have surged by approximately 40% and 25%, respectively.
The market is expected to be boosted by medical care professionals' and customers' increasing awareness of the likelihood of receiving aggressive cancer treatment over the forecast period. Additionally, an increase in hematologic malignancies-related initiatives for Research & Development (R&D) is expected to drive market revenue growth. The increasing adoption of technologically advanced genetic analysis and DNA testing for better screening and biomarker techniques for hematologic malignancies, along with the rising usage of these testing techniques to create innovative targeted medicines, are some of the major factors driving market revenue growth.
However, the high cost of hematological tests, time-consuming, difficult, and radiologically polluting tests, and constraints of PCR techniques that include reagent depletion, longer program time scales, interpretation of false positive results due to contamination, and short RNA stability in RT-PCR are restraining the market's growth. Additionally, there are concerns about accuracy and dependability of genetic testing and lack of competent specialists, particularly in developed and impoverished locations worldwide.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/5908
The global hematologic malignancies testing market is segmented into multiple myeloma, myelodysplastic syndrome, leukemia, myeloproliferative neoplasms, and lymphoma based on disease type. The leukemia segment accounted for the largest revenue share in 2021 due to rising demand for early diagnosis because of increasing prevalence of leukemia. The multiple myeloma segment is expected to register a significantly fast revenue growth rate during the forecast period due to its high level of durability, rapid advancement in melanoma therapies, and effective treatment rate.
In conclusion, the global hematologic malignancies testing market is expected to grow rapidly due to the increasing prevalence of blood cancer, rising healthcare spending, awareness among patients and healthcare professionals, and the development of a strong product pipeline.
However, the high cost of hematological tests, concerns about accuracy and dependability of genetic testing, and lack of competent specialists are restraining the market's growth. The market is segmented based on disease type, and the leukemia segment accounted for the largest revenue share in 2021, while the multiple myeloma segment is expected to register significant growth during the forecast period.
Request a customized copy of the report @
https://www.reportsanddata.com/request-customization-form/5908
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
Browse for more reports…